Sarcopenia in Ageing and Chronic Illness: Trial Endpoints and Regulatory Issues.

J Cachexia Sarcopenia Muscle · 2025 · PMC12146653 · PMID 40485364

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nearly significantno p-value reported

At the highest dose of 350 mg twice daily, treatment with 20E demonstrated a nearly significant improvement in gait speed, supported by evidence of a dose–response effect.

also in 3,287 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.